A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Completed · Phase 2
Conditions studied: Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
In brief
The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70 years.
Key facts
- Study ID
- NCT02842242
- Run by
- MyoKardia, Inc.
- People needed
- 21
- Starts
- 2016-08-01
- Expected to finish
- 2017-11-01
- Last updated by the study team
- 2021-06-08
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Arizona — Scottsdale, Arizona, United States
- Yale New Haven Hospital — New Haven, Connecticut, United States
- Tufts Medical Center — Boston, Massachusetts, United States
- Washington University St. Louis — St Louis, Missouri, United States
- Duke Health Center at Southpoint — Durham, North Carolina, United States
- Oregon Health and Science University — Portland, Oregon, United States
- Hospital of the University of Pennsylvania (Penn Heart and Vascular Center) — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.